Table 1. Studies included in this meta-analysis.

Author	Year of publication	Country	miRNA	No. of patients	Stage	Follow-up (months)	Endpoints	Expression associates with poor prognosis	Assay method	Sample
Cai H [10]	2013	China	210	92	-	105a	OS, EFS	High	RT-PCR	Tissue
Li X [19]	2014	China	17-92 cluster	117	I-III	55a	OS, EFS	High	RT-PCR	Tissue
Tian Z [23]	2014	China	128	100	-	38.89a	OS, EFS	High	RT-PCR	Tissue
Xu SH [27]	2014	China	9	79	I-III	60a	OS	High	RT-PCR	Tissue
Wang Z [26]	2014	China	214	92	-	107a	OS, EFS	High	RT-PCR	Tissue
Cheng DD [14]	2015	China	542-5p	40	-	40	EFS	High	RT-PCR	Tissue
Yu LD [29]	2015	China	130b	68	I-III	36	OS, EFS	High	RT-PCR	Tissue
Chen J [12]	2016	China	130a	86	I-IV	60a	OS, EFS	High	RT-PCR	Tissue
Zeng H [31]	2016	China	199b-5p	98	I-IV	60b	OS, EFS	High	RT-PCR	Tissue
Yang J [28]	2013	China	132	166	II-III	105a	OS, EFS	Low	RT-PCR	Tissue
Tang M [22]	2013	China	145	166	II-III	100a	OS, EFS	Low	RT-PCR	Tissue
Sarver AL [20]	2013	USA	382	8	-	194a	OS, EFS	Low	RT-PCR	Tissue
Ji F [18]	2013	China	133a	92	I-III	60a	OS	Low	RT-PCR	Tissue
Song QC [21]	2014	China	26a	144	II-III	140a	OS, EFS	Low	RT-PCR	Tissue
Cai H [11]	2014	China	340	92	-	100a	OS, EFS	Low	RT-PCR	Tissue
Arabi L [9]	2014	Switzerland	20a	57	-	112	OS	Low	RT-PCR	Tissue
Arabi L [9]	2014	Switzerland	92a	57	-	112	OS	Low	RT-PCR	Tissue
Zhou J [33]	2015	China	143	45	-	36c	OS	Low	RT-PCR	Tissue
Yuan J [30]	2015	China	451	118	II-III	80a	OS, EFS	Low	RT-PCR	Tissue
Wang W [25]	2015	China	144	67	I-IV	80a	OS	Low	RT-PCR	Tissue
Wang G [24]	2015	China	22	52	I-IV	60c	OS, EFS	Low	RT-PCR	Tissue
Han K [17]	2015	China	195	107	II-III	90a	OS	Low	RT-PCR	Tissue
Han G [16]	2015	China	124	105	II-III	80a	OS	Low	RT-PCR	Tissue
Chen J [13]	2015	China	449a	60	I-III	60b	OS	Low	RT-PCR	Tissue
Zhao J [32]	2016	China	99a	130	II-III	60a	OS, EFS	Low	RT-PCR	Tissue
Geng S [15]	2016	China	224	40	-	60	OS	Low	RT-PCR	Tissue

- Follow-up; ^amedian, ^bheterogeneity of logrank test, ^cmean

- OS, overall survival; EFS, event free survival; RT-PCR, reverse transcription polymerase chain reaction